

Hao Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10448890/publications.pdf>

Version: 2024-02-01

33
papers

965
citations

361413
20
h-index

434195
31
g-index

34
all docs

34
docs citations

34
times ranked

805
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing. <i>Bioanalysis</i> , 2019, 11, 1605-1617. | 1.5 | 6 |
| 2 | Concerted application of LC-MS and ligand binding assays to better understand exposure of a large molecule drug. <i>Bioanalysis</i> , 2018, 10, 1261-1272. | 1.5 | 3 |
| 3 | Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 9-16. | 2.8 | 8 |
| 4 | 2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 1-8. | 1.5 | 32 |
| 5 | Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. <i>Drug Metabolism and Disposition</i> , 2016, 44, 238-249. | 3.3 | 28 |
| 6 | A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 119, 145-151. | 2.8 | 6 |
| 7 | Characterization of ADME properties of [¹⁴ C]asunaprevir (BMS-650032) in humans. <i>Xenobiotica</i> , 2016, 46, 52-64. | 1.1 | 13 |
| 8 | Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 409-418. | 2.8 | 56 |
| 9 | Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. <i>Journal of Immunological Methods</i> , 2015, 416, 94-104. | 1.4 | 23 |
| 10 | Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 17-23. | 2.8 | 5 |
| 11 | Choosing the right bioanalytical assay platform(s) to support the PK assessment of protein biotherapeutic programs. <i>Bioanalysis</i> , 2015, 7, 1197-1199. | 1.5 | 2 |
| 12 | An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. <i>Bioanalysis</i> , 2014, 6, 1747-1758. | 1.5 | 23 |
| 13 | Current advances and strategies towards fully automated sample preparation for regulated LC-MS/MS bioanalysis. <i>Bioanalysis</i> , 2014, 6, 2441-2459. | 1.5 | 36 |
| 14 | Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. <i>Bioanalysis</i> , 2014, 6, 2371-2383. | 1.5 | 19 |
| 15 | A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 973, 1-8. | 2.3 | 19 |
| 16 | Sensitivity-based analytical approaches to support human absolute bioavailability studies. <i>Bioanalysis</i> , 2014, 6, 497-504. | 1.5 | 19 |
| 17 | Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay Development. <i>Analytical Chemistry</i> , 2014, 86, 2673-2680. | 6.5 | 38 |
| 18 | A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 921-922, 81-86. | 2.3 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. <i>Analytical Chemistry</i> , 2013, 85, 9859-9867. | 6.5 | 74 |
| 20 | A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis. <i>Journal of the Association for Laboratory Automation</i> , 2012, 17, 211-221. | 2.8 | 20 |
| 21 | Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. <i>Analytical Chemistry</i> , 2012, 84, 10031-10037. | 6.5 | 39 |
| 22 | A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine. <i>Journal of Chromatography A</i> , 2012, 1245, 117-121. | 3.7 | 34 |
| 23 | Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies. <i>Analytical Chemistry</i> , 2012, 84, 4844-4850. | 6.5 | 35 |
| 24 | A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. <i>Analytical Chemistry</i> , 2011, 83, 6237-6244. | 6.5 | 23 |
| 25 | A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2064-2072. | 2.3 | 14 |
| 26 | Benzo[a]pyrene-7,8-dihydrodiol Promotes Checkpoint Activation and G2/M Arrest in Human Bronchoalveolar Carcinoma H358 Cells. <i>Molecular Pharmacology</i> , 2007, 71, 744-750. | 2.3 | 30 |
| 27 | Metabolism of Benzo[a]pyrene in Human Bronchoalveolar H358 Cells Using Liquid Chromatography-Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2007, 20, 1331-1341. | 3.3 | 76 |
| 28 | Competing Roles of Aldo-Keto Reductase 1A1 and Cytochrome P4501B1 in Benzo[a]pyrene-7,8-diol Activation in Human Bronchoalveolar H358 Cells: A Role of AKRs in P4501B1 Induction. <i>Chemical Research in Toxicology</i> , 2006, 19, 68-78. | 3.3 | 42 |
| 29 | Quantification of benzo[a]pyrene diol epoxide DNA-adducts by stable isotope dilution liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 1369-1380. | 1.5 | 39 |
| 30 | Competing Roles of Cytochrome P450 1A1/1B1 and Aldo-Keto Reductase 1A1 in the Metabolic Activation of (±)-7,8-Dihydroxy-7,8-dihydro-benzo[a]pyrene in Human Bronchoalveolar Cell Extracts. <i>Chemical Research in Toxicology</i> , 2005, 18, 365-374. | 3.3 | 56 |
| 31 | Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1260-1272. | 2.0 | 32 |
| 32 | Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. <i>British Journal of Pharmacology</i> , 2004, 141, 616-623. | 5.4 | 58 |
| 33 | Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 769, 169-176. | 2.3 | 39 |